Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 83-89

  Intragumtornchai, Tanin ^a   Bunworasate, Udomsak ^a   Siritanaratkul, Noppadol ^b   Khuhapinant, Archrob ^b   Nawarawong, Weerasak ^c   Norasetthada, Lalita ^c   Lekhakula, Arnuparp ^d   Rujirojindakul, Pairaya ^d   Sirijerachai, Chittima ^e   Chansung, Kanjana ^e   Suwanban, Tawatchai ^f   Chuncharunee, Suporn ^g   Niparuck, Pimjai ^g   Wongkhantee, Somchai ^h   Mongkonsritragoon, Wichean ⁱ   Numbenjapon, Tontanai ⁱ  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f RAJAVITHI HOSPITAL   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h KHON KAEN HOSPITAL   (Thailand)

ⁱ PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Diffuse large B cell lymphoma; Health insurance; Rituximab; Thailand; Universal coverage

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THAILAND;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THAILAND; TREATMENT OUTCOME; UNIVERSAL COVERAGE;

EID: 84870893023     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.698739     Document Type: Article

References (28)

1. S akunphanit T. Universal health care coverage through pluralistic approaches: Experience from Th ailand [Internet]. Bangkok: ILO Subregional Offi ce for East Asia;2008. Available from: Http://www. ilo.org/public/english/ region/asro/bangkok/events/sis/download/paper31.pdf
2. H ughes D, Leethingdee S. Universal coverage in the land of smiles: Lessons from Th ailand's 30 baht health reform. Health Aff (Millwood) 2007;26:999-1008.
3. August 30, [in Th ai]. Bangkok, Th ailand: Ministry of Finance 1999.
4. A nnouncement of the Ministry of Finance on guideline on the reimbursement of medications in the government-based hospitals for the Civil Servant Medical Benefi t Scheme, dated August 30, 1999 [in Th ai]. Bangkok, Th ailand: Ministry of Finance; 1999. [4] Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
5. P freunjdschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with goodprognosis diff use large B-cell lymphoma: 6-year results of an openlabel randomised study of the MabTh era International Trial (MInT) Group. Lancet Oncol 2011;12:1013-1022.
6. National Drug Committee. National list of essential medicines 2008. 2nd ed. Bangkok: National Health Security Offi ce; 2009.
7. Bunworasate U, Siritanaratkul N, Khuhapinant A, et al. A nationwide prospective multicenter study of clinical features and outcomes on non-Hodgkin lymphoma in Th ailand: An analysis of 939 cases. Blood 2011;118(Suppl. 1): Abstract 2064.
8. Jaff e ES, Harris NL, Stein H,et al. World Health Organization classifi cation of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
9. C heson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
12. Cox D. Regression models and life tables. J R Stat Soc 1972;34: 187-220.
13. A predictive model for aggressive non-Hodgkin' s lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
14. M arcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as fi rst-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423. (Pubitemid 40223656)
15. H abermann TM, Weller EA, Morrison VA,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
16. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diff use large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033. (Pubitemid 46224009)
17. Announcement of the Ministry of Finance on reimbursement for health care services for the in-patients in the government-based hospitals based on the Diagnostic Related Groups (DRG), dated June 13, 2007 [in Th ai]. Bangkok, Th ailand: Ministry of Finance; 2007.
18. Guideline on health care service reimbursement, dated March 23, 2011 [in Th ai]. Bangkok, Th ailand: Bureau of Claim Administration, National Health Security Offi ce; 2011.
19. K omrokji RS, Al Ali NH, Beg MS, et al. Outcome of diff use large B-cell lymphoma in the United States has improved over time but racial disparities remain: Review of SEER data. Clin Lymphoma Myeloma Leuk 2011;11:257-260.
20. Chihara D, Oki Y, Ine Set al. Analysis of prognostic factors in peripheral T-cell lymphoma: Prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009;50:1999-2004.
21. Jones SE, Grozea PN, Metz EN. Superiority of adriamycin-containing combination chemotherapy in the treatment of diff use lymphoma: A Southwest Oncology Group study. Cancer 1979;43:417-425. (Pubitemid 9122259)
22. Coiffi er B, Th ieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the fi rst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l' Adulte. Blood 2010;116:2040- 2045.
23. National Institute for Clinical Excellence. Technology appraisal 65. Rituximab for aggressive non-Hodgkin's lymphoma. September 2003 [Internet]. Available from: Http://www.nice.org.uk/guidance/TA65
24. N ational Clinical Practice Guidelines in Oncology (NCCN Guidelines ™): Non-Hodgkin's lymphomas. Version 2.2011. [Internet]. Available from: Http://www.NCCN.org
25. Best JH, Hornberger J, Proctor SJ, et al. Cost-eff ectiveness analysis of rituximab combined with CHOP for treatment of diff use large B-cell lymphoma. Value Health 2005;8:462-470. (Pubitemid 41726099)
26. G root MT, Lugtenburg PJ, Hornberger J,et al. Cost-eff ectiveness of rituximab (MabTh era) in diff use large B-cell lymphoma in the Netherlands. Eur J Haematol 2005;74:194-202. (Pubitemid 40278488)
27. N ational list of reimbursed drugs. Taipei, Taiwan: Bureau of National Health Institute; 2008.
28. N ational list of essential medicines. Seoul, South Korea: Ministry of Health and Welfare; 2010.